---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015013"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:26:24.077414+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q1 BRIUMVI US rev $194.8M; raises FY guidance to $885-900M

## Summary
- Q1 2026 total global revenue approx $205M; BRIUMVI U.S. net product revenue $194.8M (+63% YoY).
- Net income $19.8M vs $5.1M YoY; product revenue $201.3M vs $119.7M YoY.
- Raises FY 2026 BRIUMVI U.S. net product revenue target to $885-900M; Q2 target ~$220M.
- Cash $572.8M at March 31, 2026; repurchased $100M of stock in Q1 at avg $29.28/share.
- Pipeline: ENHANCE Phase 3 data mid-2026; subcutaneous BRIUMVI data year-end 2026/Q1 2027; azer-cel data H2 2026.

## SEC filing metadata
- accession: 0001437749-26-015013
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/0001437749-26-015013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/tgtx20260227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015013
- JSON: https://secwatch.observer/filing/0001437749-26-015013.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015013.txt

## Source-grounded claims
- claim_id: cd53f0a3701a0614cac76cd9be41cec5db03ad27
  claim: TG THERAPEUTICS, INC. updated its the three months ended March 31, 2026 guidance (raised).
  evidence_excerpt: On May 6, 2026, the Company issued a press release announcing results of operations for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/0001437749-26-015013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.